Logo image of ARDX

ARDELYX INC (ARDX) Stock Fundamental Analysis

NASDAQ:ARDX - Nasdaq - US0396971071 - Common Stock - Currency: USD

5.13  +0.07 (+1.38%)

After market: 5.12 -0.01 (-0.19%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ARDX. ARDX was compared to 571 industry peers in the Biotechnology industry. ARDX may be in some trouble as it scores bad on both profitability and health. ARDX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ARDX had negative earnings in the past year.
In the past year ARDX has reported a negative cash flow from operations.
ARDX had negative earnings in each of the past 5 years.
ARDX had a negative operating cash flow in each of the past 5 years.
ARDX Yearly Net Income VS EBIT VS OCF VS FCFARDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ARDX (-8.98%) is better than 87.52% of its industry peers.
ARDX's Return On Equity of -22.58% is amongst the best of the industry. ARDX outperforms 83.60% of its industry peers.
Industry RankSector Rank
ROA -8.98%
ROE -22.58%
ROIC N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ARDX Yearly ROA, ROE, ROICARDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 84.85%, ARDX belongs to the best of the industry, outperforming 88.59% of the companies in the same industry.
ARDX's Gross Margin has been stable in the last couple of years.
ARDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
ARDX Yearly Profit, Operating, Gross MarginsARDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ARDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARDX has been increased compared to 1 year ago.
The number of shares outstanding for ARDX has been increased compared to 5 years ago.
The debt/assets ratio for ARDX is higher compared to a year ago.
ARDX Yearly Shares OutstandingARDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ARDX Yearly Total Debt VS Total AssetsARDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ARDX has an Altman-Z score of 1.22. This is a bad value and indicates that ARDX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.22, ARDX is doing good in the industry, outperforming 68.09% of the companies in the same industry.
A Debt/Equity ratio of 0.87 indicates that ARDX is somewhat dependend on debt financing.
ARDX's Debt to Equity ratio of 0.87 is on the low side compared to the rest of the industry. ARDX is outperformed by 79.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z 1.22
ROIC/WACCN/A
WACC9.77%
ARDX Yearly LT Debt VS Equity VS FCFARDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

ARDX has a Current Ratio of 4.58. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
ARDX's Current ratio of 4.58 is in line compared to the rest of the industry. ARDX outperforms 49.91% of its industry peers.
ARDX has a Quick Ratio of 4.31. This indicates that ARDX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.31, ARDX perfoms like the industry average, outperforming 50.27% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.58
Quick Ratio 4.31
ARDX Yearly Current Assets VS Current LiabilitesARDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.67% over the past year.
ARDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 168.07%.
ARDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 129.15% yearly.
EPS 1Y (TTM)45.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)168.07%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%237.95%

3.2 Future

ARDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.56% yearly.
ARDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.95% yearly.
EPS Next Y12.6%
EPS Next 2Y104.51%
EPS Next 3Y91.21%
EPS Next 5Y54.56%
Revenue Next Year14.87%
Revenue Next 2Y22.91%
Revenue Next 3Y27.01%
Revenue Next 5Y20.95%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARDX Yearly Revenue VS EstimatesARDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ARDX Yearly EPS VS EstimatesARDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ARDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARDX Price Earnings VS Forward Price EarningsARDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDX Per share dataARDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ARDX's earnings are expected to grow with 91.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.51%
EPS Next 3Y91.21%

More info and screens

0

5. Dividend

5.1 Amount

ARDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARDELYX INC

NASDAQ:ARDX (2/24/2025, 8:12:58 PM)

After market: 5.12 -0.01 (-0.19%)

5.13

+0.07 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners64.68%
Inst Owner Change-96.55%
Ins Owners1.84%
Ins Owner Change3.13%
Market Cap1.22B
Analysts85.33
Price TargetN/A
Short Float %11.48%
Short Ratio6.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)208.75%
Min EPS beat(2)94%
Max EPS beat(2)323.5%
EPS beat(4)4
Avg EPS beat(4)119.85%
Min EPS beat(4)26.89%
Max EPS beat(4)323.5%
EPS beat(8)6
Avg EPS beat(8)73.44%
EPS beat(12)10
Avg EPS beat(12)549.88%
EPS beat(16)10
Avg EPS beat(16)409.91%
Revenue beat(2)2
Avg Revenue beat(2)7.36%
Min Revenue beat(2)3.56%
Max Revenue beat(2)11.16%
Revenue beat(4)4
Avg Revenue beat(4)17.29%
Min Revenue beat(4)3.56%
Max Revenue beat(4)30.48%
Revenue beat(8)7
Avg Revenue beat(8)32.64%
Revenue beat(12)10
Avg Revenue beat(12)29.91%
Revenue beat(16)13
Avg Revenue beat(16)51.73%
PT rev (1m)-5.48%
PT rev (3m)-4.49%
EPS NQ rev (1m)1503.03%
EPS NQ rev (3m)1503.03%
EPS NY rev (1m)2.23%
EPS NY rev (3m)2.23%
Revenue NQ rev (1m)1.26%
Revenue NQ rev (3m)1.26%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.64
P/FCF N/A
P/OCF N/A
P/B 7.01
P/tB 7.01
EV/EBITDA N/A
EPS(TTM)-0.16
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS1.41
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.98%
ROE -22.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.85%
FCFM N/A
ROA(3y)-22.18%
ROA(5y)-43.77%
ROE(3y)-43.52%
ROE(5y)-79.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-0.87%
F-Score2
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.01%
Cap/Sales 0.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.58
Quick Ratio 4.31
Altman-Z 1.22
F-Score2
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)26.96%
Cap/Depr(5y)45.67%
Cap/Sales(3y)0.23%
Cap/Sales(5y)4.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y12.6%
EPS Next 2Y104.51%
EPS Next 3Y91.21%
EPS Next 5Y54.56%
Revenue 1Y (TTM)168.07%
Revenue growth 3Y220.85%
Revenue growth 5Y129.15%
Sales Q2Q%237.95%
Revenue Next Year14.87%
Revenue Next 2Y22.91%
Revenue Next 3Y27.01%
Revenue Next 5Y20.95%
EBIT growth 1Y55.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year345.81%
EBIT Next 3Y82.84%
EBIT Next 5Y62.12%
FCF growth 1Y49.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.06%
OCF growth 3YN/A
OCF growth 5YN/A